Authors: Hurwitz, E Klapper, LN Wilchek, M Yarden, Y Sela, M

Citation: E. Hurwitz et al., Inhibition of tumor growth by poly(ethylene glycol) derivatives of anti-ErbB2 antibodies, CANCER IMMU, 49(4-5), 2000, pp. 226-234

Authors: Vaisman, N Nissim, A Klapper, LN Tirosh, B Yarden, Y Sela, M

Citation: N. Vaisman et al., Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library, IMMUNOL LET, 75(1), 2000, pp. 61-67

Authors: Klapper, LN Kirschbaum, MH Sela, M Yarden, Y

Citation: Ln. Klapper et al., Biochemical and clinical implications of the ErbB/HER signaling network ofgrowth factor receptors, ADV CANC R, 77, 2000, pp. 25-79

Authors: Levkowitz, G Oved, S Klapper, LN Harari, D Lavi, S Sela, M Yarden, Y

Citation: G. Levkowitz et al., c-Cbl is a suppressor of the Neu oncogene, J BIOL CHEM, 275(45), 2000, pp. 35532-35539

Authors: Klapper, LN Waterman, H Sela, M Yarden, Y

Citation: Ln. Klapper et al., Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2, CANCER RES, 60(13), 2000, pp. 3384-3388

Authors: Klapper, LN Glathe, S Vaisman, N Hynes, NE Andrews, GC Sela, M Yarden, Y

Citation: Ln. Klapper et al., The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors, P NAS US, 96(9), 1999, pp. 4995-5000